According to the latest report by IMARC Group, titled “Infantile Spasms Therapeutics Market by Therapeutic Class (Anticonvulsants, Corticosteroids, and Others), Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others (Phase III)), Dosage (Solid, Liquid), Route of Administration (Oral, Parenteral, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Hospitals, Clinics, and Others), and Region 2025-2033,” the global infantile spasms therapeutics market size reached USD 3.8 Billion in 2024. Infantile spasms, also known as West syndrome, refers to a rare and severe form of epilepsy that typically affects infants between the ages of 3 and 12 months. They are characterized by brief symmetric muscle contractions that can cause the body or limbs to jerk or flex. They can be diagnosed by physical examination, neurological examination, magnetic resonance imaging (MRI) of the brain, and blood and urine examinations. They involve a combination of medication and therapies, such as steroids, hormone therapy with corticotropin injection gel and glucocorticoids, and antiseizure medications.
Global Infantile Spasms Therapeutics Market Trends:
The increasing incidences of infantile spasms among infants represent one of the major factors driving the demand for infantile spasms therapeutics around the world. Moreover, the rising awareness about the early signs and symptoms of infantile spasms and improved diagnostics capabilities is favoring the growth of the market. In addition, governing agencies of several countries are offering financial assistance for infantile spasms treatment to minimize healthcare expenses. Apart from this, they are financing research and development (R&D) projects to identify and develop novel therapeutic agents. This, coupled with the increasing number of clinical trials by pharmaceutical companies, is augmenting the growth of the market. Looking forward, the market value is projected to reach USD 5.2 Billion by 2033, expanding at a CAGR of 3.52% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Therapeutic Class Covered | Anticonvulsants, Corticosteroids, Others |
Drug Type Covered | Vigabatrin, Adrenocorticotropic Hormone, Other(Phase III) |
Dosage Covered | Solid, Liquid |
Route of Administration Covered | Oral, Parenteral, and Others |
Distribution Channel Covered | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy |
End User Covered | Hospitals, Clinics, Others |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800